Cellectis Report: Monthly Update on Share Capital & Voting Rights

Author: Dylan Bailey Updated: 08-07-2025 04:38 PM

Overview of Share Capital and Voting Rights

Understanding the dynamics of share capital and voting rights is crucial for investors and stakeholders in the biotechnology sector. This report provides a monthly overview of these key indicators for Cellectis, a leading company in gene editing and clinical-stage biotechnologies.

Share Capital Update

As of July 31, 2025, Cellectis reported a total of 100,325,229 shares in capital. This substantial number reflects the company's commitment to expand its operations and research initiatives in the ever-evolving biotech landscape. The total number of voting rights associated with these shares stands at an impressive 89,428,630, which allows for significant participation in corporate governance.

Details on Voting Rights

Voting rights are essential for shareholders as they determine the influence a shareholder has in corporate decisions. With 89,428,630 voting rights, Cellectis empowers its shareholders to make impactful decisions regarding the future of the company. This ensures that stakeholder interests are represented as the firm navigates through its strategic objectives.

About Cellectis

Innovative Gene Editing Company

Cellectis is at the forefront of biotechnology, employing its groundbreaking gene-editing technology to develop cell and gene therapies that could potentially save lives. The company is well known for utilizing an allogeneic approach in CAR T immunotherapies, offering ‘off-the-shelf’ solutions that are ready for immediate use by cancer patients. This innovative methodology is changing the treatment paradigm in oncology.

End-to-End Manufacturing Capabilities

One of the remarkable aspects of Cellectis is its robust in-house manufacturing capabilities. By controlling the entire value chain of cell and gene therapy production, Cellectis assures the quality and efficiency of its processes. This strategic direction places them among a select group of companies that can offer thorough oversight from development to manufacturing to distribution, ensuring high-quality therapies reach those in need.

Global Presence and Market Engagement

Cellectis is headquartered in Paris, France, and has operational hubs in New York and Raleigh, North Carolina. This international presence allows the company to engage a broader segment of the market and tap into diverse scientific communities. As a publicly traded entity, registered on both the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS), Cellectis continues to expand its footprint in the global arena.

Contact Information

If you have questions regarding this report or the company, you may reach out for additional information. For media inquiries, Pascalyne Wilson, the Director of Communications, is available at +33 (0)7 76 99 14 33 or via email at media@cellectis.com. For investor relations, contact Arthur Stril, Chief Financial Officer & Chief Business Officer, at +1 (347) 809 5980 or through investors@cellectis.com.

Frequently Asked Questions

What is the total number of shares in Cellectis' capital?

As of July 31, 2025, Cellectis has 100,325,229 shares in capital.

How many voting rights does Cellectis currently have?

Cellectis currently holds a total of 89,428,630 voting rights.

Where is Cellectis headquartered?

Cellectis is headquartered in Paris, France.

On which stock exchanges is Cellectis listed?

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS).

How does Cellectis contribute to cancer treatment?

Cellectis develops innovative CAR T immunotherapies that are ready to use, targeting cancer patients efficiently.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.